Catalyst Pharmaceuticals, Inc. announced that the Company has received notification by the United States Patent and Trademark Office (USPTO) that two additional patents covering FIRDAPSE® (amifampridine) Tablets 10 mg, were allowed and will be granted within the next two months. These new patents are for claims associated with the unique and novel, previously unknown, bioavailability of FIRDAPSE under fasting and fed conditions of dosing. FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.53 USD | -2.30% | +0.24% | -1.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.67% | 2B | |
-3.26% | 89.69B | |
+2.50% | 41.34B | |
-12.01% | 33.72B | |
+62.74% | 26.11B | |
-19.79% | 14.63B | |
-8.58% | 12.84B | |
-12.34% | 11.66B | |
-43.92% | 11.52B | |
+4.27% | 8.92B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE